Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 18 (1), 368

Impact of Resistance Training on Body Composition and Metabolic Syndrome Variables During Androgen Deprivation Therapy for Prostate Cancer: A Pilot Randomized Controlled Trial

Affiliations
Clinical Trial

Impact of Resistance Training on Body Composition and Metabolic Syndrome Variables During Androgen Deprivation Therapy for Prostate Cancer: A Pilot Randomized Controlled Trial

Jacqueline K Dawson et al. BMC Cancer.

Abstract

Background: Prostate cancer patients on androgen deprivation therapy (ADT) experience adverse effects such as lean mass loss, known as sarcopenia, fat gain, and changes in cardiometabolic factors that increase risk of metabolic syndrome (MetS). Resistance training can increase lean mass, reduce body fat, and improve physical function and quality of life, but no exercise interventions in prostate cancer patients on ADT have concomitantly improved body composition and MetS. This pilot trial investigated 12 weeks of resistance training on body composition and MetS changes in prostate cancer patients on ADT. An exploratory aim examined if a combined approach of training and protein supplementation would elicit greater changes in body composition.

Methods: Prostate cancer patients on ADT were randomized to resistance training and protein supplementation (TRAINPRO), resistance training (TRAIN), protein supplementation (PRO), or control stretching (STRETCH). Exercise groups (EXE = TRAINPRO, TRAIN) performed supervised exercise 3 days per week for 12 weeks, while non-exercise groups (NoEXE = PRO, STRETCH) performed a home-based stretching program. TRAINPRO and PRO received 50 g⋅day- 1 of whey protein. The primary outcome was change in lean mass assessed through dual energy x-ray absorptiometry. Secondary outcomes examined changes in sarcopenia, assessed through appendicular skeletal mass (ASM) index (kg/m2), body fat %, strength, physical function, quality of life, MetS score and the MetS components of waist circumference, blood pressure, glucose, high-density lipoprotein-cholesterol, and triglyceride levels.

Results: A total of 37 participants were randomized; 32 participated in the intervention (EXE n = 13; NoEXE n = 19). At baseline, 43.8% of participants were sarcopenic and 40.6% met the criteria for MetS. Post-intervention, EXE significantly improved lean mass (d = 0.9), sarcopenia prevalence (d = 0.8), body fat % (d = 1.1), strength (d = 0.8-3.0), and prostate cancer-specific quality of life (d = 0.9) compared to NoEXE (p < 0.05). No significant differences were observed between groups for physical function or MetS-related variables except waist circumference (d = 0.8).

Conclusions: A 12-week resistance training intervention effectively improved sarcopenia, body fat %, strength and quality of life in hypogonadal prostate cancer patients, but did not change MetS or physical function. PRO did not offer additional benefit in improving body composition.

Trial registration: ClinicalTrials.gov: NCT01909440 . Registered 24 July 2013.

Keywords: Body fat; Metabolic syndrome; Muscle mass; Prostate cancer; Protein supplementation; Sarcopenia; Strength training; Survivorship.

Conflict of interest statement

Ethics approval and consent to participate

The study was approved by the University of Southern California Institutional Review Board (HS-13-00315). All participants provided written consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flow of participants through the trial. EXE, exercise groups; NoEXE, non-exercise groups; TRAINPRO, resistance training protein supplementation group; TRAIN, resistance training; PRO, protein supplementation; STRETCH, control stretching

Similar articles

See all similar articles

Cited by 4 articles

References

    1. Smith M, Saad F, Egerdie B, Sieber P, Tammela T, Ke C, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012;30(26):3271–3276. doi: 10.1200/JCO.2011.38.8850. - DOI - PMC - PubMed
    1. Hamilton E, Gianatti E, Strauss B, Wentworth J, Lim-Joon D, Bolton D, et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol. 2011;74(3):377–383. doi: 10.1111/j.1365-2265.2010.03942.x. - DOI - PubMed
    1. Schulman C, Irani J, Morote J, et al. Androgen-deprivation therapy in prostate cancer: a European expert panel review. Eur Urol Suppl. 2010;9(7):675–691. doi: 10.1016/j.eursup.2010.07.001. - DOI
    1. Braga-Basaria M, Dobs A, Muller D, Carducci M, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979–3983. doi: 10.1200/JCO.2006.05.9741. - DOI - PubMed
    1. Conteduca V, Di Lorenzo G, Bozza G, Ardito R, Aieta M. Metabolic syndrome as a peculiar target for management of prostate cancer patients. Clinical genitourinary cancer. 2013;11(3):211–220. doi: 10.1016/j.clgc.2013.04.009. - DOI - PubMed

Publication types

MeSH terms

Associated data

Feedback